If one of your clinical research sites has received an FDA warning letter or FDA Form 483, your first instinct may be to panic. It may also be tempting to look for someone to blame, which is equally unhelpful.
Topics: Form 483, FDA, Warning Letters
You want to keep your trial on track, but physical distancing and travel restrictions have made it difficult. Fortunately, IMARC has experience providing remote services.
If one of your clinical research sites has received an FDA warning letter or FDA Form 483, your first instinct may be to panic. It may also be tempting to look for someone to blame, which is equally unhelpful.
Topics: Form 483, FDA, Warning Letters
Following an FDA inspection, a clinical research site may be issued an FDA Form 483 or a warning letter.
The Form 483 and FDA Warning Letter both serve a similar purpose—to inform sponsors and principal investigators of issues requiring corrective action—but there are some important differences. A Form 483 is less formal but can escalate to a warning letter in the same way a tornado watch becomes a more serious warning.
Read on to learn the differences between Form 483s and FDA Warning Letters, as well as potential changes on the horizon.
Topics: Form 483, FDA, Warning Letters
For the sixth year consecutive year, IMARC is presenting its Top 10 Warning Letter findings for your review.
Topics: BIMO Metrics, Top 10, FDA, Warning Letters
When the Food and Drug Administration (FDA) identifies significant findings with the conduct of a clinical trial during an inspection, what happens to those findings? According to a recent article published online by JAMA Internal Medicine, those findings remain hidden in plain sight.
Topics: Inspections, Charles Selfe, FDA, Warning Letters
This week is FDA Warning Letter Week at IMARC! Have you had a chance to catch up on the first three blogs that aim to help you response to the FDA? This last blog in the series attempts to take the perspective of the agency when reading your response letters.
Topics: Form 483, FDA, Warning Letters
This week is FDA Warning Letter Week at IMARC Research! Over the next four days, IMARC will provide the following blogs to help learn and generate
Topics: FDA, Warning Letters, Form 483s
The FDA Bioresearch Monitoring Program (BIMO) was created to: “Protect the rights, safety, and welfare of human research subjects involved in FDA-regulated clinical trials; Verify the accuracy and reliability of clinical trial data submitted to FDA in support of research or marketing applications; and To assess compliance with statutory requirements and FDA's regulations governing the conduct of clinical trials.” But, how exactly does FDA safeguard human subjects, ensure data integrity, and verify compliance with applicable standards?
Topics: BIMO Metrics, IMARC Research, FDA, Warning Letters
In clinical research this phrase is used to emphasize the importance of complete and accurate documentation to site staff. Still, every year we see that FDA issues multiple warning letters which cite, “You failed to maintain adequate and accurate records.”
Topics: 21 CFR 812.140, Documentation in Clinical Research, FDA, Warning Letters
While working on a recent project involving researching FDA warning letters, it astonished me the number of investigators and investigative sites who had issues with informed consent. I was surprised at the seemingly little familiarity study staff had regarding Federal Regulations when it came to the informed consent and the consenting process.
Topics: Federal Regulations, Improper Consent, Warning Letters
In thinking about working with sites to prepare for a potential FDA audit, we reviewed several of the recent FDA warning letters which had been sent to sites after audits were conducted.
Topics: Corrective Actions, FDA Audit Responses, Warning Letters
Dr. K. Kringle
Adjunct Professor of Child Psychology
Far Northern University
Topics: IRB, Warning Letters
Following an FDA inspection and exit interview, the FDA investigator will discuss the findings from an inspection and if deficiencies are found, a FDA 483 Inspectional Observations may be issued. The 483 describes any inspection findings that represent deviations from applicable agreements and regulations. The response to a FDA 483 is crucial. An article published in GxP Perspectives highlights sentence fragments from Warning Letters which seem to indicate a missed opportunity to avoid a Warning Letter following an FDA 483:
Topics: john lehmann, FDA, Warning Letters